Vera Therapeutics, Inc. (VERA)
| Market Cap | 1.85B +2.3% |
| Revenue (ttm) | 10.28M |
| Net Income | -415.31M |
| EPS | -5.91 |
| Shares Out | 72.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 184,485 |
| Open | 26.11 |
| Previous Close | 26.20 |
| Day's Range | 25.34 - 26.55 |
| 52-Week Range | 25.42 - 56.05 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 71.36 (+178.15%) |
| Earnings Date | Nov 5, 2026 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $71.36, which is an increase of 178.15% from the latest price.
News
Vera Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
TRUTAKNA generated 700 Patient Start Forms in its first 17 U.S. launch weeks, with strong physician interest and a large IgAN market opportunity. Plans include a European filing in Q1 2027, monthly dosing studies, and expansion into additional kidney diseases.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation...
Vera Therapeutics price target lowered to $29 from $34 at Wedbush
Wedbush lowered the firmās price target on Vera Therapeutics (VERA) to $29 from $34 and keeps a Neutral rating on the shares. The firm notes the company reported $10M inā¦
Vera Therapeutics price target lowered to $66 from $76 at Guggenheim
Guggenheim lowered the firmās price target on Vera Therapeutics (VERA) to $66 from $76 and keeps a Buy rating on the shares.
Vera Therapeutics price target lowered to $75 from $90 at H.C. Wainwright
H.C. Wainwright lowered the firmās price target on Vera Therapeutics (VERA) to $75 from $90 and keeps a Buy rating on the shares following the Q3 report. Published first onā¦
Vera Therapeutics reports Q3 EPS ($1.30), consensus ($1.62)
Reports Q3 revenue $10.3M, consensus $3.32M. Net product revenue was driven by the early launch momentum of Trutakna following its accelerated approval in July. āWe are excited by the earlyā¦
Vera Therapeutics Earnings Call Transcript: Q3 2026
TRUTAKNA generated $10.3M in first partial-quarter sales and received ~700 Patient Start Forms. ORIGIN 3 results showed 76% lower kidney progression risk through 104 weeks, supporting a full-approval application; cash and borrowing capacity totaled $459M pro forma.
Vera Therapeutics Earnings release: Q3 2026
Vera Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Vera Therapeutics Quarterly report: Q3 2026
Vera Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
TRUTAKNAĀ® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to...
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company's management team will participat...
Vera Therapeutics Transcript: Study update
ORIGIN 3 showed atacicept reduced eGFR loss to less than 1 mL/min/year and lowered composite kidney progression risk by 76% through week 104 in high-risk IgA nephropathy. A supplemental BLA was planned for the quarter, with full FDA approval anticipated in mid-2027.
Vera Therapeutics Press release: Study update
Vera Therapeutics issued a press release on October 22, 2026, disclosing material business information to investors.
Vera Therapeutics Slides: Study update
Vera Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 22, 2026.
Vera Therapeutics announces publication of ORIGIN 3 final efficacy analysis
Vera Therapeutics (VERA) announced that the final efficacy analysis for the ORIGIN 3 trial of TRUTAKNA in adults with primary IgA nephropathy at risk for disease progression was presented asā¦
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA⢠(atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk ...
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA ⢠(atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary sessi...
Vera Therapeutics initiated with a Market Perform at Leerink
Leerink initiated coverage of Vera Therapeutics (VERA) with a Market Perform rating and $34 price target The firm thinks Trutakna can launch āreasonably well in the near term,ā but arguesā¦
Vera Therapeutics price target lowered to $60 from $66 at BofA
BofA lowered the firmās price target on Vera Therapeutics (VERA) to $60 from $66 and keeps a Buy rating on the shares as part of the firmās Q3 EPS previewā¦
Vera Therapeutics announces ORIGIN 3 final efficacy analysis of Trutakna
Vera Therapeutics (VERA) announced that there will be multiple presentations at the American Society of Nephrology, ASN, Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The finalā¦
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA⢠(atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
ORIGIN 3 Final Efficacy Analysis of TRUTAKNA⢠(atacicept-vymj) in IgAN Will be A Featured Late-breaking Oral Presentation at Opening Plenary of ASN 2026
Vera Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Final phase III data showed TRUTAKNA significantly slowed kidney function decline and reduced risk of hard outcomes in IgAN, supporting a strong U.S. launch with over 350 patient starts in 10 weeks. The company is expanding globally, pursuing new indications, and maintains a robust financial position.
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
Why is Vera Therapeutics stock reversing its premarket gains?
Vera Therapeutics (VERA) shares ripped higher in premarket trading on September 15 as investors reacted to landmark clinical data. The biopharmaceutical firm announced that its lead therapy TRUTAKNA (...
Vera Therapeutics ORIGIN 3 study results positive, says Raymond James
After Vera Therapeutics (VERA) reported the final efficacy analysis for their pivotal ORIGIN 3 study needed for full approval of Trutakna in IgAN, Raymond James analyst Ryan Deschner called theā¦